XERS
Xeris Pharmaceuticals Inc
10.10$
-0.6%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.2% | 14.2% | -50.0% | -21.5% | -15.3% | 3.3% | -16.7% | 0.3% | 24.8% | 23.4% | 11.9% | 9.0% | 16.9% | |
| 6.9% | 7.3% | 7.9% | 6.6% | 4.9% | 5.2% | 5.2% | 4.4% | 4.1% | 3.5% | 3.9% | 3.5% | 3.7% | |
| 5.1% | 6.2% | 9.3% | 8.8% | 12.5% | 6.0% | 7.4% | 7.0% | 10.3% | 6.1% | 5.0% | 12.0% | 8.4% | |
| 9.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -22.9% | 40.2% | -13.9% | -7.0% | 16.6% | -0.8% | -15.4% | -9.6% | 8.2% | -0.4% | -0.7% | -7.3% | -0.5% | |
| 0.7% | 0.3% | 0.4% | 0.8% | 0.2% | 0.4% | 0.0% | 0.4% | 0.5% | 0.4% | 0.4% | 0.2% | 0.4% | |
| 30.3% | 33.5% | -48.4% | 9.6% | 18.3% | 16.7% | 0.0% | -0.4% | -0.1% | -0.4% | -0.4% | -0.2% | -0.3% | |
| -0.1% | -0.1% | -8.5% | -0.1% | -0.2% | -0.3% | -13.3% | -1.2% | -0.6% | -1.8% | -20.5% | -0.2% | -5.7% | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | |
| -0.1% | -0.1% | 86.6% | 1.4% | -0.2% | 0.7% | -5.2% | 1.3% | 18.6% | -0.3% | -10.6% | 2.1% | 2.0% | |
| -0.1% | 48.0% | -11.7% | -10.6% | 2.8% | 20.6% | -21.9% | 1.2% | 43.3% | 22.7% | 0.9% | 10.9% | 18.6% | |
| -30.9% | 13.9% | -50.4% | -22.4% | -15.5% | 2.9% | -16.7% | -0.1% | 24.3% | 23.0% | 11.5% | 8.7% | 16.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.